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ABSTRACT
In the vast majority of human populations, the gene encoding CASPASE-12 (CASP12) has a
premature termination codon that precludes the production of protein. However, approximately
20% of persons of recent African descent have a single nucleotide polymorphism (#rs497116;
A->G) that turns the stop codon into one encoding Arg. The subsequent functional allele is a
risk factor for sepsis as it uniquely downregulates inflammatory cytokines in African-Americans
(AA). To determine if CASP12 could be protective for systemic lupus erythematosus (SLE) in
AA, we genotyped AA SLE patients and controls. There was a weak association between
CASP12 genotype with the absence of anti-dsDNA autoantibodies in SLE patients. No effect
was seen upon serum interleukin-1 beta levels, nor was any other protective effect noted for the
CASP12 genotype, whether upon association with SLE, or any of the 11 American College of
Rheumatology classification criteria. CASP12 genotype thus does not influence the phenotype
of SLE in AA.

1. Introduction
In mice, CASPASE-12 (CASP12) modulates both the inflammatory process and the
cellular apoptotic pathway.

A truncated pseudogene (CASP12p1) resulting from a premature

termination mutation is found in all Caucasians and East Asians examined, and in 80% of
people of African lineage [1]. Thus, while most humans lack a functional CASP12 gene,
approximately 20% of persons of African descent have a functional pseudogene that is rescued
by a single nucleotide polymorphism (#rs497116; A->G) that turns the premature stop codon
into one encoding Arg [2,3]. The functional allele is a risk factor for sepsis in persons of African
descent due to its genotype-dependent ability block inflammasome and CASP1 activation [4,5]
which in turn down-regulates inflammatory cytokines such as interleukin-1β (IL1 β) in responses
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to pro-inflammatory mediators such as bacterial lipopolysaccharide [1]. In addition, knockout
mice lacking CASP12 are less susceptible to sepsis and death than wild-type mice [5].
A corollary to the observation that CASP12 is a risk factor for sepsis would be that
CASP12 is protective against some inflammatory autoimmune diseases, particularly systemic
lupus erythematosus (SLE), in AA populations. SLE is a serious inflammatory disease with
protean manifestations that can affect any organ system. The diverse nature of SLE requires
classification by the presence of no less than 4 of 11 criteria, as defined by the American
College of Rheumatology [6,7]. Gender, environment, and genetic factors influence the
development of SLE [8,9], with over 40 genes known to play a role in SLE pathogenesis [10]. A
number of these genes are specific SLE risk factors in AA individuals [9].
AA have the highest prevalence of SLE among all ethnic groups, regardless of age,
gender, or socio-economic class. They manifest the disease with greater severity and burden,
and have worse prognoses and higher mortality rates [8,11,12]. AA patients tend to have more
frequent organ system involvement, higher auto-antibody titers, and a more pronounced
pathological course. Clinically, these patients develop organ-specific damage at a faster rate
than white SLE patients [13], and are more likely to have severe disease flares [14]. We thus
chose to assess the role of CASP12 in SLE using AAs selected from the Lupus Family Registry
and Repository cohort [15].
2. Material and methods
2.1 Study population
The Lupus Family Registry and Repository (LFRR) is a large, multi-ethnic cohort of SLEaffected individuals, their unaffected family members, and healthy population-based controls
supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases [15]. Our
study group included 714 AA SLE patients and 325 healthy, population-based AA controls
(demographics provided in Table 1). Study subjects were self-defined African Americans who
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satisfied at least 4 of the 11 criteria for the classification of SLE [6,7]. Sera were stored at -80o C
until use.

2.2 DNA genotyping
CASP12 genotyping was performed in a single tube assay [16] by allele-specific polymerase
chain reaction (PCR) using primers containing a mismatch introduced at the second base from
the 3’ end to improve allele specificity [17] . Primers were C12-P1
(GAGTCACTATCGAGGAAGTCTCCATG), C12-P2X (TTCTGAACTTGACCTTTTGGGGATTC),
C12-P3X (TATCCAAGGTTTTCAAGTAGATCTAA), and P12-P4
(CTTCACATTACATTTTCTGTTTCTTCCATC). PCR parameters were an initial 60 sec of
denaturation at 94o C, 5 sec of priming at 55o C, and 5 sec of extension at 72o C, for 30 cycles,
using SpeedSTAR HS or Sapphire DNA polymerase (Takara, Madison, WI). PCR products
were analyzed on a 1% agarose gel. To verify results, the polymorphic portion of CASP12 was
subjected to DNA sequencing using a high-fidelity DNA polymerase. Sequence analysis was
sensitive enough to discriminate between homozygous and heterozygous individuals.
2.3 ELISA analysis
Serum interleukin-1β (IL-1β) levels were measured using a Biolegend (San Diego, CA) ELISAMAX Deluxe ELISA kit according to the manufacturer’s instructions.

2.4 Statistical Analyses
Pearson’s chi square statistics or Fisher’s exact p values (not adjusted for multiple testing) were
generated for full model genetic analyses of CASP12 using the PLINK software program [18].
Cytokine analyses included non-parametric 2-tailed t tests with Mann-Whitney corrections. P <
0.05 was considered statistically significant.
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3. Results
3.1 CASP12 has no overall effect on SLE in AAs
To determine if CASP12 is protective against SLE in AAs due to its anti-inflammatory
functions, we genotyped the CASP12 SNP rs497116 in a total of 714 AA patients and 325 AA
controls (all unrelated). Eight SLE patients (1.1%) were homozygous C12, 152 (21.3%) were
heterozygous p1/C12, and 554 (77.6%) were homozygous p1 (Table 2). These frequencies
were similar to our normal control group and to normal controls reported in other studies [1,3].
Allele frequencies were comparable: 88% for p1 and 12% for C12 alleles in cases; 87% for the
p1 allele and 13% for the C12 allele in controls. There was no association with CASP12
genotype and any of the 11 ACR classification criteria for SLE (Table 2) in case-control
analyses, nor was there any effect by CASP12 upon clinical criteria within patients in a caseonly design, i.e., having or lacking CASP12 did not affect a patient from being susceptible to, or
protected from any particular clinical presentation (Table 3).
The LFRR did not calculate Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) scores for their patient population. We therefore, approximated the severity of their
disease at time of enrollment by defining “severe” manifestations of SLE as any case having
renal disease, plus neurological manifestations or serositis. Using these criteria, we did not
observe any association between CASP12 genotype and the more pathological presentations of
SLE. Therefore, when evaluating SLE as a phenotype, there was no significant association
observed with CASP12.

3.2 CASP12 does not affect serum IL-1β levels in AAs with SLE
With the data suggesting that CASP12 plays a protective role in one aspect of SLE, we
sought to determine if the mechanism involved would be mediated by IL-1β, the cytokine best
known to be influenced by CASP12 [1,5]. IL-1β production by peripheral blood mononuclear
5

cells (PBMCs) is reduced in lupus patients compared to normal controls [19], while serum IL-1β
levels are elevated [20]. Our hypothesis was that IL-1β would be substantially reduced in a
genotype-dependent manner. In testing 29 subjects (15 patients and 14 controls), there was no
significant difference in IL-1β levels between patients and controls when evaluated by CASP12
genotype (Fig.1a), nor was there any difference amongst individuals, when grouped by
genotype only (Fig 1b).

3.3 CASP12 protects against dsDNA antibodies of SLE in AAs.
The effect of the CASP12 genotype was also assessed for six different autoantibodies in
a case-only analysis (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin). Of the patients for
whom we have autoantibody data, a weak but significant effect was only observed for antidsDNA, either with a genotypic (p=0.045) or allelic (p=0.032) model (Table S1).

4. Discussion
We have found that CASP12 genotype is neither a risk factor nor protective against SLE
in African-Americans. CASP12 polymorphisms do not affect any of the 11 ACR classification
criteria, but have, at best, a weak protective effect against the development of at least one
autoantibody.
While our data do not demonstrate the CASP12 genotype had a significant effect upon
serum levels of IL-1β or any symptomology of SLE, we recognize that we evaluated a small
sample. Indeed, we observe that the cases homozygous for the CASP12p1 allele have no IL1β in their serum while three of the four controls that we evaluated have between 100-400
pg/ml. As relatively low numbers of African-Americans carry both copies of CASP12 (about 13% of the population [1, 3 and our data], for the number of cases evaluated, changes in even
small numbers could affect the significance of the results, and therefore, replication studies
6

should be performed before a strong conclusion can be drawn about CASP12 genotype and
SLE, especially concerning the role of IL-1β in lupus.
Close to 200 autoantibodies have been identified in SLE patients [21].

Such

autoantibodies often function as biomarkers for disease activity, have pathogenic roles, and/or
are part of diagnostic criteria [22-24]. Given the importance of their role in SLE, we tested
whether CASP12 genotype would affect the presence or absence for six different
autoantibodies (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin). We observed, at best, a
weak but significant effect for anti-dsDNA. Yet after adjusting for multiple testing in the casecontrol and case-case analyses, no significant results remained, and no significant effects were
seen for the other autoantibodies.
In addition to CASP12, in humans the inflammatory caspase family includes CASP1 (the
best studied) [25], CASP4 and CASP5.

CASP1 triggers inflammation and mediates

inflammatory cell death by pyroptosis via the activation of IL-1β and IL18 from inactive prohormones receptors [26].

Activation of CASP1 requires assembly and activation the

inflammasome complex following danger signals transmitted from pattern recognition [27].
CASP4 and 5 are also part of the inflammasome and activated by this complex [28].
What evidence is there for overt roles for the inflammatory caspases in the pathogenesis
of autoimmunity? Other than CASP1 contributing to murine lupus [29], very little is known about
the role of CASP4 and 5 in the pathogenesis of autoimmunity [27] although data is emerging
that the latter caspases are involved in autoimmune skin [30] and bowel diseases [31], along
with SLE [32].
Given the reported downregulatory effects the protein exerts upon IL1 production via
inhibition of CASP1 [1,5] it was surprising that that we observed so few effects. We expected to
see reduced serum IL-1β levels in our patient group, with the lowest levels in the CASP12
homozygous patients, especially given that defects in the ability of PBMCs to produce IL-1β
7

occur in SLE patients [19] and decreased IL-1β levels in patient serum have been described
[20].

This was not the case. It should be considered, however, that nearly all studies on IL-1β

production in SLE patients involve groups such as Caucasians or Asians who carry the p1/p1
genotype [33]. Therefore, CASP12’s effects may be qualitative at the cellular level rather than
quantitative at the serologic level, and other inflammatory cytokines need to be examined.
If CASP12 is indeed downregulatory, it may fail to reduce serum concentrations of IL-1β
or other pathogenic cytokines below disease-inducing levels, but does so at the cellular level.
This notion is supported by our observation that CASP12 genotype is not protective against the
development of rheumatoid arthritis (RA) in AA, but is protective against RA radiologic
abnormalities [34]. Surprisingly, obese African-American children had lower serum IL6 and Creactive protein levels, as well as less macrophage infiltration into adipose tissues, if they were
CASP12-positive [35].
The key question that emerges: is CASP12 actually anti-inflammatory?
findings bring to mind “the dog that didn’t bark”.

Our own

CASP12 genotype does not influence

susceptibility or adverse events in African-Americans or black South Africans with communityacquired pneumonia [36].

In addition, susceptibility to Candida sepsis in Africans is not

affected by CASP12 genotype, nor does it have any effect on serum cytokine concentrations in
septic candidiasis patients [37] or in responses to Yersinia pestis [38]. CASP12’s effects upon
TNF production, which is elevated in all lupus patients, especially AA [39], is also contradictory
[38,40,41]. Further, while hepatitis C virus is a IL1 inducer [42], CASP12 genotype has no
effect in the clearance of this pathogen [43]. Confounding the metabolic findings described
above by Skeldon and co-workers, no protective effects were found in African-American adults
with CASP12 when metabolic parameters or C-reactive protein levels were assessed [35].
While these differences may be due to sample size, populations tested, underlying
disease states assessed, or the assay systems used, one other observation is worth noting: In
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transgenic mice carrying human CASP12, the gene is downregulated in a gender-specific
manner, due to an endogenous estrogen response element [41].

Yet there is a profound

skewing of the gender ratio in SLE: 90% of AA SLE patients are female [44] while male lupus
patients have a more severe phenotype and worse outcomes [45,46]. A protective CASP12
gene product would be expect to yield the opposite ratios.
The down-regulatory effects of CASP12 may be subtle enough that it can increase risk
for bacterial sepsis, yet not interrupt the pathogenesis of autoimmunity. It may be that in other
autoimmune or autoinflammatory disorders that CASP12 has a protective role, but thus far,
using CASP12 genotype to predict protection from, or disease outcomes in rheumatic diseases,
appears to be problematic.
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Figure Legends
Fig 1. CASP12 genotype has no effect upon serum levels of IL1β when comparing
patients and controls. p1/p1, CASP12p1 homozygous; C12/p1, CASP12p1/CASP12
heterozygous; C12/C12, CASP12 homozygous. Data represent means of two-well replicates
assayed via ELISA. Open circles, patients. Closed circles, normal controls.
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